Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021

J Infect. 2023 Jul;87(1):e1-e4. doi: 10.1016/j.jinf.2023.04.013. Epub 2023 Apr 24.

¹ Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Ph.D. Program in Medical Biotechnology, Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan.
² Departments of Laboratory Medicine and Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan; Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@gmail.com.

No abstract available

Publication types